Skip to content

24/7 dementia helpline 800-272-3900

Dementia Today

No Benefit for Dimebon in Huntington’s

Dementia TodayPublished October 30, 20124 min read

Key points

  • An antihistamine that failed to work in Alzheimer’s disease also fell short of expectations in Huntington’s disease, researchers reported.
  • Currently, medications can mitigate the symptoms of movement problems that accompany Huntington’s, but there is no treatment for its cognitive dysfunction.
  • Researchers had also speculated that the drug would alleviate the symptoms of Alzheimer’s disease, but it flopped in a major trial.
  • Patients were given placebo or 20 mg latrepirdine 3 times a day for 26 weeks.

An antihistamine that failed to work in Alzheimer’s disease also fell short of expectations in Huntington’s disease, researchers reported.

In a randomized controlled trial, latrepirdine (Dimebon) didn’t improve cognition or global function compared with placebo, Ray Dorsey, MD, of Johns Hopkins, and colleagues reported online in the Archives of Neurology.

Currently, medications can mitigate the symptoms of movement problems that accompany Huntington’s, but there is no treatment for its cognitive dysfunction.

Though it was initially developed as an antihistamine, latrepirdine was shown in some studies to aid mitochondrial function, which might be impaired in Huntington disease.

Researchers had also speculated that the drug would alleviate the symptoms of Alzheimer’s disease, but it flopped in a major trial.

Dorsey and colleagues conducted a randomized, controlled, double-blind trial at 64 centers in Australia, Europe, and North America in 403 patients with mild to moderate Huntington’s and baseline cognitive impairment.

Patients were given placebo or 20 mg latrepirdine 3 times a day for 26 weeks. Primary endpoints were improvements in cognition and global function, as measured by the Mini-Mental State Exam score and the Clinician Interview-Based Impression of Change, respectively.

Overall, the researchers found no differences in improvements in cognition between the drug and placebo groups (1.5-point improvement versus 1.3 point improvement, P=0.39).

Likewise there were no differences in global function between groups as measured by both clinician and caregiver interview (P=0.84).

And there were no significant effects on any of the secondary outcome measures including behavior, motor function, or activities of daily living, they added.

Adverse events were similar between groups (68.5% and 68%), and the most common complications were falls, worsening chorea, and somnolence.

Only fatigue and dry mouth occurred more frequently in the latrepirdine group, the researchers wrote.

They also cautioned that there was more weight gain among patients who took the drug (0.97 kg [2.14 lbs] versus 0.04 kg [0.09 lbs], P=0.01).

There are a number of reasons why the drug may not have worked in these patients, the researchers said. The failure could be due to inadequate dosing, insufficient duration of treatment, inappropriate outcome measures, or lack of therapeutic benefit in this population.

And since even the patients on placebo saw cognitive improvements, it raises questions about the effects of placebo in other Huntington’s trials, they noted.

“Although the results of this study were disappointing, the trial lays the foundation for future investigations of Huntington’s disease experimental therapeutics aimed at cognition,” Dorsey and colleagues concluded, adding that the trial was the largest “by far” of any drug aimed specifically at improving cognition in the disease.

The study was supported by grants from Medivation and Pfizer.

The researchers reported relationships with Medivation, Pfizer, Elan, SIENA, Teva, Boehringer Ingelheim, Impax, UCB, GE Healthcare, IPSEN, Novartis, Solvay, Quintiles, Biogen Idec, Allergan, GlaxoSmithKline, Bial, Lundbeck, Chelsea Therapeutics, Impax, Santhera, Merck Serono, Synosis, Schering Plough, Shire, XenoPort, Addex, Adamas, Noven, PICO-Tesla, Schwartz, Genzyme, Acadia, Molecular Biometrics, Abbott, Acorda, Aptiv, Biotie, Bioaail, Ceregene, Civitas, Clintrex, Cynapsus, Isis, Knopp, Eli Lilly, Link Medicine, LZ THerapeutics, Merz, Orion, Otsuka, Pharm2B, Phytopharm, Siena, Synagile, Vaccinex, Vectura, NeuroSearch, AOP Orphan, Medesia, Amarin, and Temmler.

###

Primary source: Archives of Neurology
Source reference: Dorsey ER, et al “A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease” Arch Neurol 2012; DOI: 10.1001/2013.jamaneurol.382.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. If a person with dementia is missing, injured or in danger, call 911 or your local emergency number.

Filed underDementia News

Worried about memory changes?

Normal aging, or an early warning sign?

Ten common changes, each set beside what is typical with age. Tick what you have noticed and see what to do next.

Open the 10-sign checklist

Getting help

Sudden changes are not just the dementia.

Dementia usually changes slowly. A sharp change over hours or days can mean an infection, delirium, a stroke or a medication problem, and needs a doctor the same day. Call 911 or your local emergency number if you see any of these:

  • Confusion that comes on suddenly, over hours or days
  • Face drooping, arm weakness or slurred speech
  • A fall, a head injury or new severe pain
  • Very drowsy or hard to wake

The free Alzheimer’s Association Helpline answers questions about memory loss, diagnosis and caregiving, day and night, in more than 200 languages (US).

If someone with dementia is missing

  1. STEP 115 minSearch close by firstCheck the house, garden, car and the places the person often walks to. Don’t spend longer than about 15 minutes.
  2. STEP 2911Then call for helpTell the operator the person has dementia and is a vulnerable adult. Police treat this as urgent.
  3. STEP 3PhotoHave details readyA recent photo, what they were wearing, medical conditions and places they used to live or work.

Based on Alzheimer’s Association guidance on wandering. Outside the US, call your local emergency number.